Clinical analysis of the combined use of ezetimibe and atorvastatin in the treatment of elderly coronary heart disease with poor blood lipid control
依折麦布与阿托伐他汀联用治疗血脂控制不佳老年冠心病的临床效果分析

摘要

目的 探析血脂控制不佳老年冠心病患者应用依折麦布联合阿托伐他汀治疗的实际成效。方法 选择2023年12月至2024年12月因血脂控制不佳于我院接受治疗的老年冠心病患者为研究样本，依据信封法随机分成参考组（40例，阿托伐他汀治疗）与实验组（40例，依折麦布联合阿托伐他汀治疗）。对比两组在血脂水平及不良反应发生率上的差异。结果 相较于参考组，实验组的TG、TC、LDL-C水平明显更低，且HDL-C水平明显更高（P<0.05）；在不良反应发生率上，实验组明显更低（P<0.05）。结论 依折麦布与阿托伐他汀联用治疗血脂控制不佳老年冠心病成效显著，能切实优化血脂指标，降低不良反应发生率。

Abstract

Objective To explore the actual effectiveness of using ezetimibe combined with atorvastatin in the treatment of elderly patients with poor blood lipid control and coronary heart disease.
Methods Elderly patients with coronary heart disease who received treatment in our hospital from December 2023 to December 2024 due to poor blood lipid control were selected as the study sample. They were randomly divided into a reference group (40 cases, treated with atorvastatin) and an experimental group (40 cases, treated with ezetimibe combined with atorvastatin) according to the envelope method. Compare the differences in blood lipid levels and incidence of adverse reactions between two groups.
Results Compared with the reference group, the experimental group had significantly lower levels of TG, TC, and LDL-C, and significantly higher levels of HDL-C (P<0.05); The incidence of adverse reactions in the experimental group was significantly lower (P<0.05).
Conclusion   The combination of ezetimibe and atorvastatin is effective in treating elderly coronary heart disease with poor blood lipid control, effectively optimizing blood lipid indicators and reducing the incidence of adverse reactions.